eaBIOGEAS Registry

Objective

To analyze current evidence on the development of autoimmune diseases associated with the use of biological therapies in patients with rheumatic diseases, based on the results published in indexed international journals and included in the PubMed data base.

Coordination

Project Coordinator

Manuel Ramos Casals, Department of Autoimmune Diseases, Hospital Clínic.

Project Members

Pilar Brito Zerón, Sandra Muñoz, Natalia Soria, Diana Galiana,Department of Autoimmune Diseases, Hospital Clínic.

Maria Laura Bertolaccini, Maria-Jose Cuadrado, Munther A. Khamashta, Lupus Unit, The Rayne Institute, St Thomas' Hospital, London, UK.

Methodology

• Diseases and drugs included in the study:
  Recent evidence on the triggering of autoimmune diseases after the use of approved biological agents (infliximab, etanercept, adalimumab, anakinra, rituximab), in adult patients with rheumatologic, digestive or cutaneous disease, was analyzed.


• Literature search
  A literature search (PubMed, January 1990-December 2006) was performed. Only original articles (not reviews) published in indexed journals that include adult patients (age > 18 years) and contain the minimum information required for the registry were included. Congress abstracts, unpublished results (“in press” or “personal communication”) were not included.